Stock 2500 VENUS MEDTECH (HANGZHOU) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Venus Medtech (Hangzhou) Inc. Stock

Equities

2500

CNE100003PJ8

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E.
Other stock markets
 03:08:30 2023-11-22 am EST 		5-day change 1st Jan Change
5.62 HKD -0.71% Intraday chart for Venus Medtech (Hangzhou) Inc. -.--% -.--%
Apr. 01 Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% MT
Mar. 28 Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2023 491M 67.81M 531M Sales 2024 * 730M 101M 789M Capitalization 2.26B 312M 2.44B
Net income 2023 -721M -99.5M -779M Net income 2024 * -293M -40.44M -317M EV / Sales 2023 4.6 x
Net cash position 2023 * 410M 56.53M 442M Net Debt 2024 * 125M 17.27M 135M EV / Sales 2024 * 3.26 x
P/E ratio 2023
-3.13 x
P/E ratio 2024 *
-7.89 x
Employees 865
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.87%
More Fundamentals * Assessed data

Chart Venus Medtech (Hangzhou) Inc.

Dynamic Chart

Latest news about Venus Medtech (Hangzhou) Inc.

Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% MT
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Venus Medtech Inc.(SEHK:2500) dropped from S&P Global BMI Index CI
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away CI
Venus Medtech Names Former 3SBio Finance Chief as CFO MT
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer CI
Venus Medtech Gets Trading Resumption Guidance MT
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China MT
Venus Medtech Inc. Announces Executive Changes CI
Venus Medtech Names Joint CEO MT
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023 CI
Venus Medtech's H1 Attributable Loss Widens MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news

Press releases Venus Medtech (Hangzhou) Inc.

Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval AQ
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023 AQ
Confirmatory clinical trial of Liwen RF™ ablation system in China concluded AQ
Venus Medtech to showcase its structural heart treatments at London Valves 2022 AQ
Venus Medtech to showcase its structural heart treatments at London Valves 2022 PR
More press releases

Quotes and Performance

1 day-0.71%
6 months+45.97%
More quotes

Highs and lows

1 year
3.74
Extreme 3.74
11.50
3 years
3.74
Extreme 3.74
75.00
5 years
3.74
Extreme 3.74
97.00
10 years
3.74
Extreme 3.74
97.00
More quotes

Managers and Directors - Venus Medtech (Hangzhou) Inc.

Managers TitleAgeSince
Hou-Sen Lim CEO
 Chief Executive Officer 50 16-11-30
Fei Wang DFI
 Director of Finance/CFO 47 23-01-03
Meirong Liu BRD
 Director/Board Member 47 17-10-31
Members of the board TitleAgeSince
Hou-Sen Lim CEO
 Chief Executive Officer 50 16-11-30
Ting Yuk Wu CHM
 Chairman 69 18-11-25
Wei Wang BRD
 Director/Board Member 41 18-11-25
More insiders

ETFs positioned on Venus Medtech (Hangzhou) Inc.

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +1.11% -
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.00% 4 M€ -4.41% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
More ETFs positioned on Venus Medtech (Hangzhou) Inc.

Company Profile

Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-08-28 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Venus Medtech (Hangzhou) Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
5.157 CNY
Average target price
7.414 CNY
Spread / Average Target
+43.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

1st Jan change Capi.
VENUS MEDTECH (HANGZHOU) INC. Stock Venus Medtech (Hangzhou) Inc.
-.--% 314M
STRYKER CORPORATION Stock Stryker Corporation
+12.07% 128B
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.04% 10.51B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+0.91% 8.71B
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+16.72% 7B
GLAUKOS CORPORATION Stock Glaukos Corporation
+25.15% 5.02B
AXONICS, INC. Stock Axonics, Inc.
+7.17% 3.39B
ENOVIS CORPORATION Stock Enovis Corporation
-1.36% 3.02B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-8.73% 2.07B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-10.15% 2.06B
Medical Devices & Implants
  1. Stock Market
  2. Equities
  3. 2500 Stock